Ronaxan 20 Tablet 20mg - per Tablet

Description

Ronaxan may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase Ronaxan if you have or are in the process of arranging such a prescription. See information bar for further details.  

Ronaxan 20 Tablet 20mg

20mg doxycycline hyclate. For the full list of excipients, see below. Pharmaceutical form Round, biconvex, light yellow to yellow scored tablet. The tablets can be divided into equal parts. Clinical particulars Target species 20mg Ronaxan tablets are indicated for use in both cats and dogs, 100mg Ronaxan tablets are indicated for use in dogs only.

Indications for use

Ronaxan is used for the treatment of respiratory tract infections in cats and dogs, including rhinitis, tonsillitis, bronchopneumonia and feline respiratory disease, due to organisms sensitive to doxycycline including: Pasteurella spp., Bordetella bronchiseptica, Staphylococcus aureus and other Staphylococcus spp., and Streptococcus spp. Treatment of arthropod-borne Ehrlichia canis infection in cats and dogs. Contra-indications Do not use in pregnant animals.

Do not use Ronaxan in known cases of hypersensitivity to the active ingredient. Vomiting, oesophagitis and oesophageal ulcerations have been reported as side effects following doxycycline therapy, and Ronaxan should not therefore be administered to patients with dysphagia or diseases accompanied by vomiting. Special warnings for each target species None known. Special precautions for use in animals Do not exceed the recommended dosage. Ronaxan Tablets should be administered at feeding time. Special precautions to be taken by the person administering the product to animals Wash hands thoroughly after use. Handle the tablets with care if you know you are hypersensitive (allergic) to tetracycline. In case of accidental ingestion, seek medical advice. Adverse reactions Photodermatitis has occurred following tetracycline therapy after exposure to intense sunlight or ultraviolet light. Use of tetracycline during the period of tooth development may lead to tooth discolouration. Doxycycline, because of its lower affinity for calcium, carries a lower risk than other tetracyclines. Refer also to section 'Contra-indications'. Use of Ronaxan during pregnancy, lactation or lay Laboratory studies have not revealed any teratogenic, or embryotoxic effect of doxycycline in the rat and rabbit. However, as there is no information available in the target species, use is not recommended during pregnancy.

Interactions Cross resistance to other tetracyclines can occur. Ronaxan should not be used concurrently with other antibiotics especially bactericidal drugs such as the β-lactams. The half-life of doxycycline is reduced by concurrent administration of barbiturates or phenytoin. Simultaneous administration of oral absorbents, iron preparations and antacids should be avoided as they reduce doxycycline availability. Amounts to be administered and administration route The tablets are for oral administration. The dosage of Ronaxan is 10mg doxycycline per kilogram of bodyweight (one 20mg tablet per 2 kg or one 100 mg tablet per 10 kg of bodyweight), administered daily for up to five days. In order to adjust the dosage, the tablets can be divided into two equal parts. For treatment of infections caused by Ehrlichia canis the dose is 10 mg/kg/day for 28 days. Complete eradication of the pathogen is not always achieved but extended treatment for 28 days leads to a resolution of the clinical signs and a reduction of the bacterial load. Longer duration of treatment, based on a benefit-risk assessment by the responsible veterinarian, may be required in severe and chronic ehrlichiosis. All treated patients should be regularly monitored even after clinical cure. Tablets should be administered at feeding time. Overdose The toxicity and tolerance studies have shown that this product is very well tolerated in cats after five times the recommended dose. Raised levels of SGPT, GGT, SAP and total bilirubin were noted in dogs which received three or five times the recommended dose. Some vomiting can occur in dogs with five times the recommended dosage. Pharmacological particulars Doxycycline is a second generation, broad spectrum cycline belonging to the tetracycline family. ATCvet code: QJ01AA02 Pharmacodynamic properties It is active against a large number of Gram positive and Gram negative pathogens including strains resistant to first generation tetracyclines.

It is essentially bacteriostatic; it inhibits the bacterial protein synthesis by blocking binding of transfer RNA to the messenger RNA-ribosome complex. Pharmacokinetic properties After oral administration in dogs and cats at the recommended dose of 10 mg/kg, doxycycline is rapidly absorbed reaching the maximal plasma concentration in about 3 hours (Tmax). The peak concentration (Cmax) is 4.5 μg/ml and 3.8 μg/ml in dogs and cats respectively.

The oral bioavailability of Ronaxan after repeated administration is approximately 45% in both species, and is not affected by the presence of food. In spite of a high protein binding rate, the volume of distribution of doxycycline is high demonstrating that doxycycline is broadly distributed in organs and tissues. Doxycycline is mainly excreted as unchanged drug and eliminated in faeces and urine. Mean elimination half-life is 7.8 hours in dogs and 5.8 hours in cats Pharmaceutical particulars Excipients Magnesium Stearate, Microcrystalline Cellulose. Major incompatibilities None known. Shelf life Shelf life of the product as packaged for sale: 2 years. Special precautions for storage Do not store Ronaxan above 25 °C. Store in a dry place. Protect from light. Immediate packaging Packs of 5 blister strips each containing 10 tablets. Disposal Any unused product or waste materials derived from such products should be disposed of in accordance with local requirements. Marketing Authorisation Number Vm 08327/4068 Vm 08327/4069 Significant changes Legal category

Legal category:

Ronaxan is a POM-V (Pet Prescription Required)